-
Voter swings raise midterm alarm bells for Trump's Republicans
-
Australia dodges call for arrest of visiting Israel president
-
Countries using internet blackouts to boost censorship: Proton
-
Top US news anchor pleads with kidnappers for mom's life
-
Thailand's pilot PM on course to keep top job
-
The coming end of ISS, symbol of an era of global cooperation
-
New crew set to launch for ISS after medical evacuation
-
Family affair: Thailand waning dynasty still election kingmaker
-
Japan's first woman PM tipped for thumping election win
-
Stocks in retreat as traders reconsider tech investment
-
LA officials call for Olympic chief to resign over Epstein file emails
-
Ukraine, Russia, US to start second day of war talks
-
Fiji football legend returns home to captain first pro club
-
Trump attacks US electoral system with call to 'nationalize' voting
-
Barry Manilow cancels Las Vegas shows but 'doing great' post-surgery
-
US households become increasingly strained in diverging economy
-
Four dead men: the cold case that engulfed a Colombian cycling star
-
Super Bowl stars stake claims for Olympic flag football
-
On a roll, Brazilian cinema seizes its moment
-
Rising euro, falling inflation in focus at ECB meeting
-
AI to track icebergs adrift at sea in boon for science
-
Indigenous Brazilians protest Amazon river dredging for grain exports
-
Google's annual revenue tops $400 bn for first time, AI investments rise
-
Last US-Russia nuclear treaty ends in 'grave moment' for world
-
Man City brush aside Newcastle to reach League Cup final
-
Guardiola wants permission for Guehi to play in League Cup final
-
Boxer Khelif reveals 'hormone treatments' before Paris Olympics
-
'Bad Boy,' 'Little Pablo' and Mordisco: the men on a US-Colombia hitlist
-
BHP damages trial over Brazil mine disaster to open in 2027
-
Dallas deals Davis to Wizards in blockbuster NBA trade: report
-
Iran-US talks back on, as Trump warns supreme leader
-
Lens cruise into French Cup quarters, Endrick sends Lyon through
-
No.1 Scheffler excited for Koepka return from LIV Golf
-
Curling quietly kicks off sports programme at 2026 Winter Olympics
-
Undav pokes Stuttgart past Kiel into German Cup semis
-
Germany goalkeeper Ter Stegen to undergo surgery
-
Bezos-led Washington Post announces 'painful' job cuts
-
Iran says US talks are on, as Trump warns supreme leader
-
Gaza health officials say strikes kill 24 after Israel says officer wounded
-
Empress's crown dropped in Louvre heist to be fully restored: museum
-
UK PM says Mandelson 'lied' about Epstein relations
-
Shai to miss NBA All-Star Game with abdominal strain
-
Trump suggests 'softer touch' needed on immigration
-
From 'flop' to Super Bowl favorite: Sam Darnold's second act
-
Man sentenced to life in prison for plotting to kill Trump in 2024
-
Native Americans on high alert over Minneapolis crackdown
-
Dallas deals Davis to Wizards in blockbuster NBA deal: report
-
Russia 'no longer bound' by nuclear arms limits as treaty with US ends
-
Panama hits back after China warns of 'heavy price' in ports row
-
Strike kills guerrillas as US, Colombia agree to target narco bosses
Indonesia approves first homegrown Covid-19 vaccine
Indonesia has approved its first locally developed Covid-19 vaccine for emergency use, the head of the country's public health agency said Friday, hailing it as a step toward "the nation's independence in access to medicine".
Jakarta has stressed the importance of developing national vaccines since the beginning of the pandemicbut it currently relies on China's Sinovac and the Western-made Moderna and Pfizer-BioNTech mRNA jabs.
The IndoVac jab, developed by state-owned pharmaceutical company Bio Farma and Texas-based Baylor College of Medicine, can now be used as a primary dose for an unvaccinated or partially vaccinated adult in the world's fourth most-populous country.
"The development... of a domestic vaccine is a pride for us Indonesians as a foundation and as the first step to achieve the nation's independence in access to medicine," head of the national food and drugs agency (BPOM) Penny Lukito said at a press conference Friday.
The medical chief said IndoVac had shown an efficacy rate of 92 percent, while there were no reports of death linked to it in trials and reported side effects were "generally mild".
A clinical study to use it as a booster jab is underway, Lukito said.
The agency also announced it had granted emergency use approval for an mRNA vaccine developed in China, becoming the first country to do so.
The inoculation developed by Walvax Biotechnology will be locally produced in Indonesia, the BPOM chief said.
The homegrown IndoVac jab has been granted a halal certificate, meaning it can be administered in line with the Islamic faith in Muslim-majority Indonesia.
Indonesia became the epicentre of Asia's Covid-19 pandemic in July last year as the Delta variant swept through the country.
Daily cases declined significantly by the end of the year but the spread of Omicron brought confirmed cases back to 30,000 a day.
It has since seen another sharp fall in case numbers andeliminated quarantine requirements for vaccinated travellers.
In total,Southeast Asia's largest economy has reported over 6.4 million confirmed cases with nearly 160,000 deaths.
Vaccination rollout has also been relatively slow compared to developed nations, with less than two-thirds of the population of 270 million receiving two jabs.
B.Khalifa--SF-PST